DJIA 18,126.12 -36.87 -0.20%
NASDAQ 5,097.98 -8.62 -0.17%
S&P 500 2,120.79 -2.69 -0.13%
market minute promo

GlaxoSmithKline (NYSE: GSK)

44.79 0.18 (0.40%)

REAL-TIME: Last trade at

Extended Hours: $45.18 $0.39 (0.87%)
Quote as of (NYSE)



company name or ticker

Recent Quotes

GSK $44.79 0.40%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $44.49
Previous Close $44.61
Daily Range $44.39 - $44.81
52-Week Range $41.25 - $54.78
Market Cap $108.2B
P/E Ratio 15.33
Dividend (Yield) $2.31 (5.7%)
Ex-Dividend Date
Dividend Pay Date
05/13/15
07/09/15
Volume 1,895,548
Average Daily Volume 3,942,077
Current FY EPS $2.52

Sector

Healthcare

Industry

Drug Makers

GlaxoSmithKline (GSK) Description

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Website: http://www.gsk.com/

News & Commentary Rss Feed

Veeva's Earnings Growth Leaves Investors Unimpressed

The life-sciences-focused cloud-computing company once again posted solid growth in sales and profits, but investors wanted more.

Did BioMarin Bet on the Wrong Experimental DMD Drug?

Sarepta Therapeutics may hold a key advantage over BioMarin in the race to bring a game-changing Duchenne muscular dystrophy drug to market. Here's why.

Why Dividend Investors Should Love These 5% Yielding European Stocks

Big Pharma Companies Are Betting On Regenerative Medicine - Should You?

Sector Leaders See 5.9% Advantage For 5 Highest-Yield, Lowest-Priced May Dividend Dogs

Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

9 International Dividend Dogs With Upside Potential

Buy-Rated Dividend Stocks: Top 3 Companies: DFT, GSK, ORI

Endo International Acquires Par Pharmaceuticals For $8 Billion

Following Hepatitis C, This Could Be the Next Disease Researchers Cure

With an effective cure for hepatitis C now in place after decades of research, we asked three of our top healthcare analysts which disease they believed researchers may cross off the list next. Here's what they had to say.

See More GSK News...

GSK's Top Competitors

GSK $44.79 (0.40%)
Current stock: GSK
JNJ $101.15 (0.02%)
Current stock: JNJ
NVS $104.25 (0.70%)
Current stock: NVS
RHHBY $37.40 (1.38%)
Current stock: RHHBY